<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Candida guilliermondii is rarely isolated from humans </plain></SENT>
<SENT sid="1" pm="."><plain>We describe a case of disseminated C. guilliermondii with associated purulent <z:hpo ids='HP_0001701'>pericarditis</z:hpo>, despite high-dose <z:chebi fb="1" ids="2682">amphotericin B</z:chebi> (AmB), in a 19-year-old female with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> who underwent BMT </plain></SENT>
<SENT sid="2" pm="."><plain>In vitro susceptibility studies of the 13 clinical isolates, two control strains and one environmental isolate revealed a minimum inhibitory concentration (MIC) range of (0.19-1.56 micrograms/ml) for AmB and (1.25-10 micrograms/ml) for <z:chebi fb="2" ids="46081">fluconazole</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Pulsed-field gradient gel electrophoresis was performed to evaluate possible similarities between strains </plain></SENT>
<SENT sid="4" pm="."><plain>This case is significant for several reasons, the high degree and prolonged duration of <z:e sem="disease" ids="C0085082" disease_type="Disease or Syndrome" abbrv="">fungemia</z:e> despite high-dose AmB and concomitant <z:chebi fb="1" ids="5100">flucytosine</z:chebi>, the change in in vitro susceptibility during therapy, the initial misidentification of the yeast isolate, and the invasiveness of the organism </plain></SENT>
<SENT sid="5" pm="."><plain>The poor response to therapy may have been due to the severe and sustained <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and the high MICs of C. guilliermondii to AmB </plain></SENT>
</text></document>